[go: up one dir, main page]

CO5580797A2 - Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos - Google Patents

Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos

Info

Publication number
CO5580797A2
CO5580797A2 CO05048853A CO05048853A CO5580797A2 CO 5580797 A2 CO5580797 A2 CO 5580797A2 CO 05048853 A CO05048853 A CO 05048853A CO 05048853 A CO05048853 A CO 05048853A CO 5580797 A2 CO5580797 A2 CO 5580797A2
Authority
CO
Colombia
Prior art keywords
sec
antibodies
treatment
same
myeloid leukemia
Prior art date
Application number
CO05048853A
Other languages
English (en)
Inventor
Mary G Hoffee
Original Assignee
Inmunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmunogen Inc filed Critical Inmunogen Inc
Publication of CO5580797A2 publication Critical patent/CO5580797A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1.- Un anticuerpo aislado o un fragmento de enlace de epítope del mismo, que comprende por lo menos una región de determinación complementaria, que tiene una secuencia de aminoácido seleccionada del grupo que consiste en NOs. ID. SEC: 1-6:SYYIH (NO. ID. SEC:1), VIYPGNDDISYNQKFXG (NO. ID. SEC:2), en donde X es K o Q, EVRLRYFDV (NO. ID. SEC:3), KSSQSVFFSSSQKNYLA (NO. ID. SEC:4), WASTRES (NO. ID. SEC:5), HQYLSSRT (NO. ID. SEC:6), y que tiene la habilidad para enlazar D33.
CO05048853A 2002-11-07 2005-05-20 Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos CO5580797A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42433202P 2002-11-07 2002-11-07

Publications (1)

Publication Number Publication Date
CO5580797A2 true CO5580797A2 (es) 2005-11-30

Family

ID=32312793

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05048853A CO5580797A2 (es) 2002-11-07 2005-05-20 Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos

Country Status (24)

Country Link
US (10) US7557189B2 (es)
EP (1) EP1578446B1 (es)
JP (1) JP5354835B2 (es)
KR (1) KR20050059332A (es)
CN (2) CN102875680B (es)
AU (1) AU2003285878B2 (es)
BR (1) BR0316101A (es)
CA (1) CA2504818C (es)
CO (1) CO5580797A2 (es)
CR (1) CR7853A (es)
CY (1) CY1116406T1 (es)
DK (1) DK1578446T3 (es)
EA (1) EA010570B1 (es)
EC (1) ECSP055831A (es)
ES (1) ES2539627T3 (es)
HU (1) HUE026914T2 (es)
IL (2) IL168295A (es)
MX (1) MXPA05004712A (es)
NO (1) NO338498B1 (es)
NZ (1) NZ539395A (es)
PT (1) PT1578446E (es)
SI (1) SI1578446T1 (es)
WO (1) WO2004043344A2 (es)
ZA (1) ZA200503075B (es)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050059332A (ko) * 2002-11-07 2005-06-17 이뮤노젠 아이엔씨 항-씨디33 항체와 이를 이용한 급성 골수성 백혈병의치료방법
EP1799259B1 (en) * 2004-10-12 2012-12-05 Crucell Holland B.V. Binding molecules for the detection of cancer
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
WO2006086733A2 (en) 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
NZ595430A (en) 2005-08-24 2013-05-31 Immunogen Inc Process for preparing maytansinoid antibody conjugates
GB0521991D0 (en) * 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
EA020324B1 (ru) 2006-07-18 2014-10-30 Санофи-Авентис АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2008058021A2 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
HUE027593T2 (en) * 2007-04-12 2016-11-28 Brigham & Womens Hospital Inc ABCB5 targeting cancer therapy
DK2019104T3 (da) 2007-07-19 2013-12-16 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater, og terapeutisk anvendelse deraf
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
CN104524592B (zh) 2008-04-30 2018-06-05 伊缪诺金公司 交联剂和它们的用途
MA33276B1 (fr) 2009-04-20 2012-05-02 Oxford Biotherapeutics Ltd Anticorps spécifiques à la cadhérine-17
KR101947176B1 (ko) 2009-06-03 2019-02-12 이뮤노젠 아이엔씨 접합 방법
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
SG178991A1 (en) * 2009-09-03 2012-04-27 Schering Corp Anti-gitr antibodies
DE102009045006A1 (de) * 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
JP2013506709A (ja) 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
US8524240B2 (en) 2009-10-26 2013-09-03 Djordje Atanackovic Diagnosis and therapy of hematological malignancies
CA2777542A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
US20120282274A1 (en) * 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
SMT201700139T1 (it) 2010-02-24 2017-05-08 Immunogen Inc Immunoconiugati contro il recettore 1 del folato e relativi usi
WO2011109108A1 (en) * 2010-03-04 2011-09-09 Vet Therapeutics Inc. Monoclonal antibodies directed to cd20
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
WO2011109662A1 (en) 2010-03-04 2011-09-09 Vet Therapeutics, Inc. Monoclonal antibodies directed to cd52
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
MX2013004476A (es) * 2010-10-20 2013-06-28 Oxford Biotherapeutics Ltd Anticuerpos.
WO2012074097A1 (ja) * 2010-12-03 2012-06-07 協和発酵キリン株式会社 抗ｃｄ３３抗体
EP2487242A1 (en) 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
SMT201900181T1 (it) 2011-02-15 2019-05-10 Immunogen Inc Metodi di preparazione di coniugati
EP2686020B1 (en) 2011-03-17 2017-02-22 The University of Birmingham Re-directed immunotherapy
EA201991268A3 (ru) 2011-03-29 2020-01-31 Иммуноджен, Инк. Получение конъюгатов "майтансиноид-антитело" одностадийным способом
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
BR112013032928A2 (pt) 2011-06-21 2017-01-24 Immunogen Inc "derivados de maitansinoide com ligante de peptídeo e conjugados dos mesmos, composição farmacêutica que os compreende e uso dos mesmos"
EA034989B1 (ru) 2011-10-28 2020-04-15 Тева Фармасьютикал Австралия Пти Лтд Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон
RU2620068C2 (ru) 2011-11-23 2017-05-22 МЕДИММЬЮН, ЭлЭлСи Связывающие молекулы, специфичные по отношению к her3, и их применения
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20130309223A1 (en) * 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
CN102768283B (zh) * 2012-07-23 2015-03-04 北京大学人民医院 一种检测或辅助检测髓系白血病细胞分化阶段的试剂盒
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
MX362514B (es) 2012-08-31 2019-01-22 Immunogen Inc Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
HK1213288A1 (zh) 2012-10-04 2016-06-30 Immunogen, Inc. 使用pvdf膜純化細胞結合劑細胞毒性劑綴合物
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JP6423804B2 (ja) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
PL3016512T3 (pl) 2013-07-05 2020-09-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rozpuszczalny CD33 do leczenia zespołów mielodysplastycznych (MDS)
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
EP3461845B1 (en) * 2013-12-13 2020-09-16 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
MX371092B (es) * 2013-12-16 2020-01-16 Genentech Inc Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
CN106062002B (zh) * 2013-12-17 2021-05-04 埃姆医疗有限公司 抵抗骨髓增生障碍或淋巴组织增生障碍的手段和方法
JP6673848B2 (ja) * 2014-04-03 2020-03-25 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫療法のためのｃｄ３３特異的キメラ抗原受容体
PT3128997T (pt) 2014-04-08 2020-09-04 Boston Pharmaceuticals Inc Moléculas de ligação específicas para il-21 e suas utilizações
HK1232127A1 (zh) 2014-04-11 2018-01-05 Medimmune, Llc 双特异性her2抗体
EP3145542A4 (en) * 2014-05-20 2018-01-17 ImmunoGen, Inc. Methods for characterizing and treating acute myeloid leukemia
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
EP3722316A1 (en) * 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
CA2958882A1 (en) * 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
US9381256B2 (en) 2014-09-03 2016-07-05 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
MX2017002758A (es) 2014-09-03 2017-10-20 Immunogen Inc Derivados de benzodiazepina citotoxicos.
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
US9867831B2 (en) * 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
PT3590962T (pt) * 2014-10-23 2021-12-15 Singh Molecular Medicine Llc Anticorpos de domínio único dirigidos contra antigénios intracelulares
PT3218406T (pt) 2014-11-10 2021-06-17 Medimmune Ltd Moléculas de ligação específicas para cd73 e seus usos
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
CN107592813A (zh) 2014-11-19 2018-01-16 伊缪诺金公司 用于制备细胞结合剂‑细胞毒性剂缀合物的方法
WO2016089960A1 (en) * 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
KR102329836B1 (ko) 2015-01-26 2021-11-19 셀렉티스 암 면역치료를 위한 항-CLL1 특이적 단일-체인 키메라 항원 수용체들(scCARS)
AU2016215604B2 (en) 2015-02-02 2020-08-13 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
CN107849148B (zh) 2015-05-21 2023-09-19 哈普恩治疗公司 三特异性结合蛋白质及使用方法
KR102537102B1 (ko) 2015-05-29 2023-05-25 엠피베나 테라퓨틱스, 인크. 이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
AU2016276981B2 (en) 2015-06-12 2022-10-06 Alector Llc Anti-CD33 antibodies and methods of use thereof
KR20240063203A (ko) 2015-06-29 2024-05-09 이뮤노젠 아이엔씨 항-cd123 항체 및 이들의 접합체와 유도체
HUE052616T2 (hu) 2015-06-29 2021-05-28 Immunogen Inc Ciszteinmódosított antitestek konjugátumai
ES2959663T3 (es) 2015-11-10 2024-02-27 Medimmune Llc Moléculas de unión específicas para ASCT2 y usos de las mismas
WO2017087789A1 (en) 2015-11-19 2017-05-26 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
JP2019501139A (ja) 2015-11-25 2019-01-17 イミュノジェン・インコーポレーテッド 医薬製剤及びその使用
KR20180105233A (ko) 2016-02-05 2018-09-27 이뮤노젠 아이엔씨 세포 결합제-세포독성제 접합체를 제조하기 위한 효율적인 방법
PL3426680T3 (pl) 2016-03-10 2025-03-31 Acceleron Pharma Inc. Białka wiążące receptor aktywiny typu 2 i ich zastosowania
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
JP7103950B2 (ja) 2016-04-22 2022-07-20 アクセレロン ファーマ インコーポレーテッド Ａｌｋ７結合性タンパク質及びその使用
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
LT3464318T (lt) 2016-06-02 2021-06-25 Abbvie Inc. Gliukokortikoidų receptorių agonistas ir jo imunokonjugatai
EP3463463A4 (en) 2016-06-03 2020-01-15 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
US11191771B2 (en) 2016-06-09 2021-12-07 Seagen Inc. Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
PE20191319A1 (es) * 2016-09-20 2019-09-24 Bayer Pharma AG Anticuerpos novedosos contra el factor xi y sus usos
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CN110300600A (zh) * 2016-11-02 2019-10-01 伊缪诺金公司 利用抗体-药物缀合物和parp抑制剂的组合治疗
CN116813690A (zh) 2016-11-23 2023-09-29 伊缪诺金公司 苯并二氮䓬衍生物的选择性磺化
MX2019005772A (es) 2016-11-23 2019-10-02 Bioverativ Therapeutics Inc Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x.
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
SG11201907693VA (en) 2017-02-28 2019-09-27 Immunogen Inc Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
TW201839001A (zh) 2017-04-20 2018-11-01 美商伊繆諾金公司 細胞毒性苯并二氮平衍生物及其綴合物
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN113896792B (zh) 2017-05-12 2025-08-22 哈普恩治疗公司 间皮素结合蛋白质
MA49152A (fr) * 2017-05-17 2020-03-25 Immunogen Inc Schémas posologiques d'immunoconjugués anti-cd33
CN110662765B (zh) 2017-08-03 2023-09-29 艾利妥 抗cd33抗体及其使用方法
US10301319B2 (en) 2017-09-20 2019-05-28 Ph Pharma Co., Ltd. Thailanstatin analogs
CA3075896A1 (en) 2017-09-22 2019-03-28 Immunogen, Inc. Methods of preventing methionine oxidation in immunoconjugates
KR102425983B1 (ko) 2017-10-13 2022-07-29 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
TW201922294A (zh) 2017-10-31 2019-06-16 美商伊繆諾金公司 抗體-藥物結合物與阿糖胞苷之組合治療
TWI827575B (zh) 2017-12-28 2024-01-01 美商伊繆諾金公司 苯二氮平衍生物
CA3091184A1 (en) 2018-02-14 2019-08-22 Viela Bio, Inc. Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
AU2019232762B2 (en) * 2018-03-08 2023-11-16 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
EP3765031A4 (en) 2018-03-14 2022-03-23 Memorial Sloan Kettering Cancer Center Anti-polysialic acid antibodies and uses thereof
TW202003048A (zh) 2018-05-15 2020-01-16 美商伊繆諾金公司 用抗體-藥物偶聯物及flt3抑制劑之組合治療
EP3796942A1 (en) 2018-05-23 2021-03-31 ADC Therapeutics SA Molecular adjuvant
AU2019275076B2 (en) * 2018-05-23 2024-12-19 National University Of Singapore Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
TWI890660B (zh) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
KR20210063351A (ko) 2018-08-28 2021-06-01 암브룩스, 인코포레이티드 항-cd3 항체 폴레이트 생체접합체 및 이들의 용도
AU2019331018A1 (en) * 2018-08-31 2021-03-11 Alector Llc Anti-cd33 antibodies and methods of use thereof
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
EP3849565A4 (en) * 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
EP3856242A4 (en) * 2018-09-25 2022-05-18 Academia Sinica ANTI-SIGLEC ANTIBODIES, PHARMACEUTICAL COMPOSITION THEREOF AND USES THEREOF
US20210324076A1 (en) * 2018-10-12 2021-10-21 Amphivena Therapeutics Inc Cd33×cd3 binding proteins for treating inflammatory conditions and diseases
SG11202103832SA (en) * 2018-11-07 2021-05-28 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
EP3883961A1 (en) 2018-11-20 2021-09-29 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
WO2020123947A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
TW202102270A (zh) 2019-03-21 2021-01-16 美商伊繆諾金公司 製備細胞結合劑-藥物結合物之方法
TW202102506A (zh) 2019-03-29 2021-01-16 美商伊繆諾金公司 苯二氮平衍生物
SG11202110922QA (en) 2019-04-26 2021-10-28 Immunogen Inc Camptothecin derivatives
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
US20230092679A1 (en) 2019-05-20 2023-03-23 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2020264211A1 (en) * 2019-06-26 2020-12-30 Memorial Sloan Kettering Cancer Center Anti-cd33 antibodies for treating cancer
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN116670268A (zh) 2019-11-22 2023-08-29 免疫医疗有限公司 包含e2泛素或泛素样缀合结构域和用于特异性蛋白质降解的靶向结构域的融合蛋白
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
EP4135846A1 (en) * 2020-04-14 2023-02-22 VIR Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
WO2022053650A1 (en) 2020-09-11 2022-03-17 Medimmune Limited Therapeutic b7-h4 binding molecules
IL301264A (en) 2020-09-12 2023-05-01 Medimmune Ltd A scoring method for anti-B7H4 antibody-drug therapy
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN116761635A (zh) 2020-11-24 2023-09-15 诺华股份有限公司 Bcl-xl抑制剂抗体药物缀合物及其使用方法
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
EP4284394A1 (en) 2021-01-26 2023-12-06 Cytocares (Shanghai) Inc. Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
WO2022195028A2 (en) 2021-03-18 2022-09-22 Medimmune Limited Therapeutic binding molecules
EP4337689A1 (en) 2021-05-12 2024-03-20 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
WO2024249925A1 (en) * 2023-06-01 2024-12-05 Research Institute At Nationwide Children's Hospital Cd-33 protein-binding compositions and methods related thereto
US20250051463A1 (en) 2023-07-31 2025-02-13 Astrazeneca Ab Cd123 antibody-drug conjugates and methods of using the same
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
ES2152216T3 (es) 1989-12-14 2001-02-01 Sloan Kettering Inst Cancer Usos terapeuticos de la region hipervariable del anticuerpo monoclonal m195 y constructos de la misma.
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
US6759045B2 (en) * 2000-08-08 2004-07-06 Immunomedics, Inc. Immunotherapy for chronic myelocytic leukemia
ES2372686T3 (es) * 2001-01-26 2012-01-25 Inhibitex, Inc. Anitcuerpos monoclonales dirigidos contra la proteína clfa y modo de empleo en el tratamiento y prevención de infecciones.
KR20050059332A (ko) * 2002-11-07 2005-06-17 이뮤노젠 아이엔씨 항-씨디33 항체와 이를 이용한 급성 골수성 백혈병의치료방법
EP1868649A4 (en) * 2005-04-15 2011-06-29 Immunogen Inc ELIMINATION OF A POPULATION OF HETEROGENEOUS OR MIXED CELLS IN TUMORS
EP2300052A4 (en) * 2008-06-16 2012-11-14 Immunogen Inc NEW SYNERGISTIC EFFECTS
EP3145542A4 (en) * 2014-05-20 2018-01-17 ImmunoGen, Inc. Methods for characterizing and treating acute myeloid leukemia

Also Published As

Publication number Publication date
KR20050059332A (ko) 2005-06-17
US20090291090A1 (en) 2009-11-26
CN102875680B (zh) 2015-04-22
US20140248267A1 (en) 2014-09-04
HUE026914T2 (en) 2016-08-29
EP1578446A4 (en) 2008-07-30
US8337855B2 (en) 2012-12-25
US20050118183A1 (en) 2005-06-02
US10000566B2 (en) 2018-06-19
US20080167458A1 (en) 2008-07-10
US7342110B2 (en) 2008-03-11
US20130078241A1 (en) 2013-03-28
US8747851B2 (en) 2014-06-10
EP1578446A2 (en) 2005-09-28
SI1578446T1 (sl) 2015-07-31
HK1091132A1 (en) 2007-01-12
JP2006505277A (ja) 2006-02-16
US20060177455A1 (en) 2006-08-10
AU2003285878A1 (en) 2004-06-03
NO338498B1 (no) 2016-08-22
CN1795009A (zh) 2006-06-28
US20180362646A1 (en) 2018-12-20
US20110206700A1 (en) 2011-08-25
IL168295A (en) 2011-02-28
US9359442B2 (en) 2016-06-07
US8119787B2 (en) 2012-02-21
WO2004043344A2 (en) 2004-05-27
NO20052693L (no) 2005-06-06
CA2504818C (en) 2013-04-23
PT1578446E (pt) 2015-07-22
NZ539395A (en) 2009-01-31
CR7853A (es) 2005-12-16
CN1795009B (zh) 2014-07-09
US20160362490A1 (en) 2016-12-15
ZA200503075B (en) 2006-09-27
NO20052693D0 (no) 2005-06-06
CN102875680A (zh) 2013-01-16
CY1116406T1 (el) 2017-02-08
WO2004043344A3 (en) 2004-12-09
EP1578446B1 (en) 2015-04-08
EA010570B1 (ru) 2008-10-30
ES2539627T3 (es) 2015-07-02
ECSP055831A (es) 2005-08-11
JP5354835B2 (ja) 2013-11-27
CA2504818A1 (en) 2004-05-27
US7557189B2 (en) 2009-07-07
MXPA05004712A (es) 2005-11-23
AU2003285878B2 (en) 2011-04-28
EA200500778A1 (ru) 2006-02-24
BR0316101A (pt) 2005-09-27
DK1578446T3 (en) 2015-06-29
US20110008840A1 (en) 2011-01-13
IL211385A0 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
CO5580797A2 (es) Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
ATE439380T1 (de) Methoden zur herstellung humaner monoklonaler antikörper
DK1325033T3 (da) Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
NO953601D0 (no) Nukleinsyre som koder for en tumorreksjonsantigenforlöper
EA200400510A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
DE60322188D1 (de) Zytokin (zcytor17-ligand)
DE60211535D1 (de) Verfahren zur herstellung von 2,5-diformylfuran aus kohlenhydraten
NO20031687D0 (no) Veksthormonsekretagoger
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
ES2180323T3 (es) Procedimiento mejorado para la obtencion simultanea de 6-aminocapronitrilo y hexametilendiamina.
BR9812837A (pt) Processo para fazer um composto, e, composto
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
PE20030282A1 (es) Anticuerpos de interleucina-1- beta
CO5280147A1 (es) Anticuerpo humano monoclonal
EE200300092A (et) EDb-fibronektiinidomeeni retseptor
ATE370163T1 (de) Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen
ATE472337T1 (de) Pharmazeutische zusammensetzung aus f(ab) 2- fragmenten von antikörpern und verfahren zu ihrer herstellung
DE60114608D1 (de) Verfahren zur herstellung von anthracyclinederivaten
DE602004016006D1 (de) Screening-verfahren
DE60108105D1 (de) Verfahren zur Herstellung von 5-substituierten Isobenzofuranen

Legal Events

Date Code Title Description
FC Application refused